1-1 of 1 results for subject:Pfizer
Librarians' tools
- Search time
- 0.183 seconds
- Solr query time
- 0.003 seconds
- Search query
- subject:Pfizer
- We searched for
- subject_t:Pfizer OR subject_ses:61578
Year
X
2017
Type
House
Session
Month
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health, what meetings representatives from NICE (a) have had and (b) plan to have with Pfizer during the consultation period for palbociclib (Ibrance) since the publication of the draft guidance on that drug on 3 February 2017.
To ask the Secretary of State for Health, what meetings representatives from NICE (a) have had and (b) plan to have with Pfizer during the consultation period for palbociclib (Ibrance) since the publication of the draft guidance on that drug on 3 February 2017.
Asked by
Simon Burns
(Conservative)
Answered by
Baroness Blackwood of North Oxford
(Conservative)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
20 February 2017
For answer on
23 February 2017
Answered on
23 February 2017
The National Institute for Health and Care Excellence has advised that a meeting with Pfizer to discuss the appraisal of palbociclib took place on 22 February 2017.
Subjects
National Institute for Health and Care Excellence; Pfizer; Palbociclib
Date
23 February 2017
Reference
64599
House
House of Commons